I would have a number of questions about this study, which was apparently run and written up by the "DRACO" patent holder.
The results are largely from cell culture so any talk about a "cure for a broad range of viruses" in the press release is premature bullshit to say the least.
There were some mice studies, along with this statement in the paper: "We have also demonstrated that DRACOs can rescue mice challenged with H1N1 influenza" - for which evidence are examination of harvested organs after two days, and three graphs showing separation for mortality between treatment and control (buffer) groups out 10 days or so (time plot ends at that point). Searching the paper, I finally find by looking at the morbidity graph that we're talking about 13 mice per group for one type of DRACO intraperitoneal administration, 5 per group for the other type of DRACO i.p, and 12 mice per group for intranasal administration.
In addition, as the authors themselves note, how much cell death could be tolerated in the face of chronic viral infection remains to be seen.
This is a very preliminary trial. There are years of work before this even approaches meriting mention of a "cure".
The results are largely from cell culture so any talk about a "cure for a broad range of viruses" in the press release is premature bullshit to say the least.
There were some mice studies, along with this statement in the paper: "We have also demonstrated that DRACOs can rescue mice challenged with H1N1 influenza" - for which evidence are examination of harvested organs after two days, and three graphs showing separation for mortality between treatment and control (buffer) groups out 10 days or so (time plot ends at that point). Searching the paper, I finally find by looking at the morbidity graph that we're talking about 13 mice per group for one type of DRACO intraperitoneal administration, 5 per group for the other type of DRACO i.p, and 12 mice per group for intranasal administration.
In addition, as the authors themselves note, how much cell death could be tolerated in the face of chronic viral infection remains to be seen.
This is a very preliminary trial. There are years of work before this even approaches meriting mention of a "cure".